Myomo, Inc., a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury. The company serves orthotics and prosthetics practices or clinics, as well as the veteran administration and other hospitals through orthotics and prosthetics providers, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
Phone+1-617-9969058
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees22
OptionableNot Optionable
Myomo (NYSEAMERICAN:MYO) Frequently Asked Questions
What is Myomo's stock symbol?
Myomo trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MYO."
How were Myomo's earnings last quarter?
Myomo Inc (NYSEAMERICAN:MYO) issued its quarterly earnings results on Tuesday, August, 7th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.02. The company earned $0.63 million during the quarter, compared to analysts' expectations of $0.62 million. View Myomo's Earnings History.
When is Myomo's next earnings date?
What price target have analysts set for MYO?
2 equities research analysts have issued 1-year price targets for Myomo's shares. Their forecasts range from $7.00 to $12.00. On average, they expect Myomo's stock price to reach $9.50 in the next year. This suggests a possible upside of 642.2% from the stock's current price. View Analyst Price Targets for Myomo.
What is the consensus analysts' recommendation for Myomo?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myomo in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myomo.
Has Myomo been receiving favorable news coverage?
Media stories about MYO stock have been trending somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Myomo earned a news sentiment score of 1.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
Are investors shorting Myomo?
Myomo saw a decrease in short interest in January. As of January 31st, there was short interest totalling 545,305 shares, a decrease of 10.3% from the January 15th total of 608,064 shares. Based on an average daily trading volume, of 47,869 shares, the short-interest ratio is presently 11.4 days. Currently, 5.3% of the shares of the stock are sold short. View Myomo's Current Options Chain.
Who are some of Myomo's key competitors?
Some companies that are related to Myomo include Protech Home Medical (PHM), Electromed (ELMD), Osprey Medical (OSP), Universal Biosensors (UBI), Resonance Health (RHT), EMvision Medical Devices (EMV), Anteo Diagnostics (ADO), GI Dynamics (GID), Aurora Spine (ASG), LBT Innovations (LBT), Azure Healthcare (AZV), Micron Solutions (MICR), Activecare (ACAR), Advanced Oncotherapy (AVO) and Airware Labs (AIRW).
Who are Myomo's key executives?
Myomo's management team includes the folowing people:
- Mr. Paul R. Gudonis, Chairman, Pres & CEO (Age 64)
- Ms. Davie Mendelsohn RN, VP of Sales & Clinical Services (Age 65)
- Mr. Jonathan Naft, VP & GM (Age 54)
- Mr. Ralph A. Goldwasser, Chief Financial Officer (Age 71)
- Mr. Clifford J. Conneighton, Chief Marketing Officer (Age 69)
Who are Myomo's major shareholders?
Myomo's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (0.38%).
Which institutional investors are buying Myomo stock?
MYO stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp.
How do I buy shares of Myomo?
Shares of MYO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myomo's stock price today?
One share of MYO stock can currently be purchased for approximately $1.28.
How big of a company is Myomo?
Myomo has a market capitalization of $15.92 million. Myomo employs 22 workers across the globe.
What is Myomo's official website?
How can I contact Myomo?
Myomo's mailing address is One Broadway, 14Th Floor, CAMBRIDGE, MA 02142, United States. The company can be reached via phone at +1-617-9969058.
MarketBeat Community Rating for Myomo (NYSEAMERICAN MYO)
MarketBeat's community ratings are surveys of what our community members think about Myomo and other stocks. Vote "Outperform" if you believe MYO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYO will underperform the S&P 500 over the long term. You may vote once every thirty days.
